ROIVW

Roivant Sciences Ltd. [ROIVW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ROIVW Stock Summary

In the News

ROIVW Financial details

Company Rating
-
Market Cap
0
Income
4.32B
Revenue
123.24M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
620
Optionable
No
Shortable
Yes
Earnings
31 Dec 2022
P/E
-8397.33
Forward P/E
-
PEG
172.19
P/S
116.11
P/B
9462.47
P/C
-
P/FCF
-10.77
Quick Ratio
6.02
Current Ratio
6.37
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
5.35
EPS next Y
-
EPS next Q
-
EPS this Y
25.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.6%
Revenue last 5Y
92.41%
Revenue Q/Q
0.11%
EPS Q/Q
-1692.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-48%
ROE
-80%
ROC
-0.57%
Gross Margin
80%
Oper. Margin
-1364%
Profit Margin
-1306%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.75-2.9199
52W High
+37.5%
52W Low
+37.5%
RSI
-
Rel Volume
-
Avg Volume
-
Volume
37.83K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
2.75
Change
-3.85%

Something similar

Top by Market Cap
AAPL
DHR-PB
CMC.DE
LLY
GOOG
Same Sector
MICR
PKTX
4528.T
PRFX
2689.T
Check Those
DIG
DVOL
NEOGEN.NS
0KZA.L
VER-PF
Similar Market Cap
TRZ.TO
BLYAX
0LK6.L
601066.SS
002219.SZ

Company Profile

Healthcare Biotechnology

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.